Japan proposes lower generic starting prices to boost uptake
This article was originally published in Scrip
The Japanese government has proposed cutting the initial reimbursement price of first-time generics to improve the uptake of such products, as part of wider ongoing drug pricing reform discussions due to be finalised by next spring.
You may also be interested in...
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.